Cancellation of Entries for Kinds of Medical Devices from the Australian Register of Therapeutic Goods - Bausch & Lomb Australia Pty Ltd - 161568

Overview

The Therapeutic Goods Act 1989, enacted to regulate therapeutic goods including medicines, medical devices, and blood and blood components, was introduced to address the need for stringent oversight of products available in the Australian market to ensure they meet safety, quality, and efficacy standards. The Act provides a comprehensive framework for the regulation of therapeutic goods, ensuring that only products that meet prescribed standards are available to the public. The policy objective of the Act is to protect public health by ensuring that therapeutic goods are safe, of high quality, and perform as claimed. The Therapeutic Goods Administration (TGA), acting on behalf of the Australian Government, administers the Act and is responsible for the regulation of therapeutic goods. In this instance, the TGA has exercised its power under Section 41GP of the Act to cancel the entry of a specific kind of medical device from the Australian Register of Therapeutic Goods due to the sponsor’s failure to provide the requested information within the stipulated timeframe, thus ensuring compliance with the regulatory requirements for the safety and efficacy of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to various entities involved in the therapeutic goods industry, including sponsors, manufacturers, and importers of therapeutic goods. The Act governs the regulation and oversight of therapeutic goods in Australia, including medical devices, and establishes the Australian Register of Therapeutic Goods (ARTG). The scope of the Act extends nationally across the Commonwealth of Australia, with specific provisions that may be supplemented by subordinate instruments. In the case of the cancellation of entries for kinds of medical devices from the ARTG, the Act provides for the removal of a device's listing if certain conditions are not met, such as failure to provide requested information within the specified timeframe. The cancellation of the listed lubricant, eye product, with the ARTG entry number 161568, and manufactured by Bausch & Lomb Inc (USA), serves as an example of this enforcement mechanism. This cancellation is applicable nationally, impacting the sponsor, Bausch & Lomb Australia Pty Ltd, and any other related parties involved in the distribution or use of the device within Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes provisions for the regulation of therapeutic goods, including medical devices, within Australia. Section 41GP allows for the publication of decisions to cancel entries from the Australian Register of Therapeutic Goods (ARTG). In this instance, section 41GP is used to notify the public of the cancellation of a specific medical device entry from the ARTG. The device in question, a lubricant for the eye, is identified by its ARTG number, 161568, and was sponsored by Bausch & Lomb Australia Pty Ltd, with Bausch & Lomb Inc (USA) as the manufacturer. The decision to cancel this entry was made on 30 August 2013 and took effect from 1 October 2013. The cancellation of the entry from the ARTG, as detailed in the notice, was due to the sponsor's failure to provide the Therapeutic Goods Administration (TGA) with the information requested under Section 41JA of the Act within the required timeframe. This section mandates that sponsors must submit certain information regarding the safety and efficacy of the medical devices they are responsible for, ensuring that these products meet the necessary standards before they can be listed in the ARTG. The failure to comply with this requirement led to the cancellation under Section 41GN(1)(c) of the Act, which permits the TGA to remove entries from the ARTG when certain conditions are not met. Entities governed by the Act, such as sponsors of medical devices, are required to adhere to several obligations to maintain their products in the ARTG. These obligations include timely submission of requested information to the TGA, ensuring that the information provided is accurate and complete, and maintaining compliance with all relevant legislative requirements. Failure to meet these obligations can result in the cancellation of the product's entry from the ARTG, as demonstrated in this case. The Act imposes both civil and criminal consequences for breaches of its provisions. In this context, the cancellation of the medical device's entry from the ARTG is a civil consequence for non-compliance with the information submission requirements under Section 41JA. While the specific maximum penalties for breaches of the Act are not detailed in the notice, the Act generally provides for fines and, in more severe cases, imprisonment. The penalties serve to enforce compliance and uphold the standards for therapeutic goods in Australia, ensuring public safety and the efficacy of medical devices available in the market.